Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Combined With Chidamide in Relapsed/Refractory Extranodal NK/T Cell Lymphoma
NCT03598959Phase 2Unknown
- Sponsor
- Sichuan University
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib oral solution, tucidinostat in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sichuan University. Status: unknown.
02
Drugs
tofacitinib oral solutiontucidinostat
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03598959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598959.